BMRN Biomarin Pharmaceutical Inc

Price (delayed)

$84.765

Market cap

$16.1B

P/E Ratio

77.77

Dividend/share

N/A

EPS

$1.09

Enterprise value

$16.44B

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for serious and life-threatening rare and ultra-rare genetic diseases. The Company's portfolio consists of six commercialized products and ...

Highlights
Biomarin Pharmaceutical's EPS has surged by 195% YoY and by 22% QoQ
The net income has surged by 187% year-on-year and by 23% since the previous quarter
BMRN's quick ratio is down by 47% year-on-year but it is up by 7% since the previous quarter

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
189.88M
Market cap
$16.1B
Enterprise value
$16.44B
Valuations
Price to book (P/B)
3.15
Price to sales (P/S)
6.48
EV/EBIT
64.57
EV/EBITDA
45.68
EV/Sales
6.65
Earnings
Revenue
$2.47B
EBIT
$254.53M
EBITDA
$359.85M
Free cash flow
$191.82M
Per share
EPS
$1.09
Free cash flow per share
$1.02
Book value per share
$26.89
Revenue per share
$13.09
TBVPS
$33.87
Balance sheet
Total assets
$6.87B
Total liabilities
$1.8B
Debt
$1.09B
Equity
$5.07B
Working capital
$1.9B
Liquidity
Debt to equity
0.21
Current ratio
2.74
Quick ratio
1.55
Net debt/EBITDA
0.95
Margins
EBITDA margin
14.6%
Gross margin
79.2%
Net margin
8.3%
Operating margin
7.6%
Efficiency
Return on assets
3%
Return on equity
4.2%
Return on invested capital
4.5%
Return on capital employed
4.4%
Return on sales
10.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-0.64%
1 week
-1.31%
1 month
1.18%
1 year
-3.37%
YTD
-12.09%
QTD
2.96%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$2.47B
Gross profit
$1.96B
Operating income
$187.21M
Net income
$205.46M
Gross margin
79.2%
Net margin
8.3%
The net income has surged by 187% year-on-year and by 23% since the previous quarter
The net margin has soared by 152% year-on-year and by 20% since the previous quarter
The operating income has surged by 151% year-on-year and by 18% since the previous quarter
Biomarin Pharmaceutical's operating margin has soared by 124% YoY and by 17% from the previous quarter

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
77.77
P/B
3.15
P/S
6.48
EV/EBIT
64.57
EV/EBITDA
45.68
EV/Sales
6.65
Biomarin Pharmaceutical's EPS has surged by 195% YoY and by 22% QoQ
BMRN's P/E is 63% below its 5-year quarterly average of 211.2 and 33% below its last 4 quarters average of 117.5
The stock's price to book (P/B) is 19% less than its 5-year quarterly average of 3.9 and 7% less than its last 4 quarters average of 3.4
The equity has grown by 9% YoY and by 2.5% from the previous quarter
BMRN's price to sales (P/S) is 20% less than its 5-year quarterly average of 8.1 and 9% less than its last 4 quarters average of 7.2
The revenue has grown by 14% YoY and by 2.2% from the previous quarter

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 181% YoY and by 25% from the previous quarter
BMRN's return on assets has surged by 173% year-on-year and by 20% since the previous quarter
The ROE has soared by 163% YoY and by 20% from the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 151% YoY and by 21% QoQ

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
BMRN's quick ratio is down by 47% year-on-year but it is up by 7% since the previous quarter
The company's current ratio fell by 42% YoY but it rose by 9% QoQ
The debt is 79% smaller than the equity
The equity has grown by 9% YoY and by 2.5% from the previous quarter
BMRN's debt to equity is down by 9% year-on-year and by 4.5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.